Skip to main content

FDA-ASPHO Pediatric Hematology/Oncology Educational Program

Advance Your Expertise in Pediatric Hematology/Oncology Drug Development and Regulatory Review

FDA Logo 225The US Food and Drug Administration (FDA) and ASPHO have partnered to cosponsor an 8-month interactive educational program designed for early career pediatric hematology/oncology clinicians and researchers. This program addresses a critical gap in training by providing learners with a foundational understanding of pediatric hematology/oncology drug-development and the regulatory review process.

The curriculum includes the following topics, among others:

  • Pediatric hematology/oncology drug regulation
  • The Investigational New Drug (IND), New Drug Application (NDA), and Biologic License Application (BLA) processes
  • Expedited drug development pathways
  • Early phase clinical trials
  • Clinical trial design and efficacy endpoint considerations
  • Pediatric hematology/oncology disease-specific considerations (eg, clinical practice, biomarker development, etc.)
  • International drug development considerations

Program Highlights

  • Duration: 8 months
  • Format
    • Half day, in-person kick-off session in conjunction with the ASPHO Conference April 29, 2026, in Minneapolis, MN
    • 7 monthly virtual sessions (approximately 3 hours each)
    • Approximately 20 hours of virtual learning
    • Virtual session will include brief didactics, large group discussion, breakout sessions, and case discussions of approved hematology & oncology drugs
  • Cost: Free! Participants also receive 50% off ASPHO Conference registration
  • Cohort Size: Limited to 20 participants

Eligibility

  • Current ASPHO membership sustained for the duration of the program
  • Pediatric hematology/oncology early career clinicians and researchers—3rd-year fellows through 10 years post-fellowship
  • Commitment to attend the in-person session in Minneapolis, April 29, 2026, and all virtual meetings for the duration of the 8-month program
  • International applicants welcome (must meet visa requirements for in-person session at time of application)

Participant Expectations

  • Active participation in all sessions
  • Pre-reading and brief assignments (~1–1.5 hours per session)
  • Camera on for virtual sessions

Apply Now!
Application Deadline: Monday, December 29, 2025, 3 pm CT

Application Requirements

  • Online application form
  • Curriculum vitae
  • Letter of support from program director (3rd year fellow applicants only)
  • Attestation of ability to participate fully in the program

The FDA and ASPHO welcome applications from young investigators and/or clinicians for this prestigious program. It is ASPHO's goal to ensure participants adequately reflect U.S.-based geographic, demographic, and specialty representation in its programming selection. 

Contact

For questions, please email This email address is being protected from spambots. You need JavaScript enabled to view it. .